JPH093064A - Novel 5-pyrroyl-6-halogeno-2- pyridylmethylsulfinylbenzimidazole derivative, and its production - Google Patents

Abstract

PURPOSE: To obtain the subject new compound useful for prevention and/or treatment of stomach ulcer and duodenal ulcer, high in enzyme inhibition effect, gastric secretoion suppressive effect and acid-degree lowering effect and free from toxity.

CONSTITUTION: This compound is expressed by formula I (X is S, SO, SO₂; Y is a halogen; R¹ and R² are each H, an alkyl; R³ is H, a 1-8C alkyl, 1- piperidinyl, 4-morpholinyl, 4-methylpiperadin-1-yl, etc.; R⁴ and R⁵ are each H, a 1-5C alkyl, etc.) or its pharmaceutically permissible salt, for example, 2-[[(4- methoxy-3-methyl)-2-pyridinyl]methylthio]-5-(1H-pyrrol-1-yl)-6-fluoro-1H- benzoimidazole. The compound of formula I is obtained by carrying out the reaction of a compound of formula II with a compound of formula III (L is a halogen, an esterified hydroxyl or an acyloxy) in the presence of a base in an organic solvent.

COPYRIGHT: (C)1997,JPO

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel 5-pyrrolyl-6-halogeno-2-pyridylmethylsulfinylbenzimidazole derivative having pharmacological activity useful as an agent for preventing and treating gastric / duodenal ulcer. More specifically, the present invention relates to a novel 5-pyrrolyl-6-halogeno-2-pyridylmethylsulfinylbenzimidazole derivative represented by the following general formula (I), or a pharmaceutically acceptable salt thereof.

[0002]

[Chemical 7]

In the formula, X represents S, SO or SO ₂ ,
Y represents a halogen atom, R ¹ and R ² each independently represent a hydrogen atom or an alkyl group, and R ³ represents a hydrogen atom, a C ₁ -C ₈ alkyl group, —SR ⁶ , —N (R
⁷ ) ₂ , 1-piperidinyl group, 4-morpholinyl group, 4
—Methylpiperazin-1-yl group, 1-pyrrolidinyl group, or a group of formula —OR ⁶ or —O (CH ₂ ) _m —Z, wherein R ⁶ is a C ₁ -C ₄ alkyl group, alkenyl C ₂ -C ₄ substituted, cycloalkyl group optionally C ₃ -C ₁₀ substituted, fluoroalkyl group C ₂ -C _5, or by one or more halogen atoms or a halogen atom, C ₁ that may be
Each independently represent substituted phenyl group or a benzyl group with an alkyl group or an alkoxy group -C _4, R ⁷ represents a hydrogen atom or an alkyl group C ₁ -C _5, Z has the formula -O (CH ^{_{2) p -OR 8, -O (}} CH
_{2) q} -R ^9, or _{-O (CH 2) r O (} CH 2) s -
Shows a group of OR ^10, p and q each independently represent an integer of 1 to 3, r and s are,
Each independently represents an integer of 1 to 5;
⁸ represents a hydrogen atom, a lower alkyl group, an aryl group or an aralkyl group; R ⁹ represents a hydrogen atom, an alkoxycarbonyl, an aryl group or a heteroaryl group;
¹⁰ is a hydrogen atom or a lower alkyl group, m is 2
Represents an integer of any of 1 to 10, wherein R ⁴ and R ⁵ are
Each independently either a hydrogen atom or an alkyl group C ₁ -C _5, when together with the carbon atom to which R ⁴ and R ⁵ is in contact with the pyridine ring to form a ring, R ⁴ and R ³ or R ³ and R ⁵ is -CH = CH-CH = CH-,-
_{O (CH 2) n -,} - O (CH 2) n O -, - CH
₂ (CH ₂ ) _n — or —OCH ＝ CH—, where n is an integer of 1 to 4.

The present invention also provides a process for producing the compound of the above general formula (I) or a pharmaceutically acceptable salt thereof, and a compound of the above general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention relates to a composition for preventing and / or treating gastric / duodenal ulcer, which comprises a salt.

[0005]

2. Description of the Related Art Gastric and duodenal ulcers cause mental stress,
It is a gastrointestinal disorder caused by various causes such as eating habits, intake of irritating beverages and foods. The main disease site is the lower esophagus, the stomach, or the duodenum. In addition, there are other unusual cases such as the presence of a gastric mucosa in the small intestine, secretion of gastric fluid from the gastric mucosa, and ulceration. The mechanism of peptic ulcer development is classified into two types: a case where the aggressive factors such as stomach acid and pepsin are strengthened, and a case where the corresponding protective factors are weakened and cannot prevent the aggressive factors. In the case of duodenal ulcer, enhanced aggressive factors have been found to be the main etiology. In the case of gastric ulcer, weakening of protective factors is known to be the cause, although there are some differences depending on the site.

[0006] At present, preparations used for treating such gastric and duodenal ulcer include antacids for neutralizing gastric acid, anti-pepsin agents, gastric mucosal protective agents, and anticholinergic agents for suppressing gastric acid secretion. agents, parasympathetic blockers, H ₂ - or the like receptor antagonists and proton pump inhibitors.

[0007]

In recent years, antacids and agents for treating central nervous system gastric ulcer have problems such as insufficient drug efficacy and side effects when taken for a long period of time. H _2- which is an anti-gastric / duodenal ulcer drug
The use of receptor antagonists is increasing.

Further, recently developed 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl] -1H of the following structural formula (A)
-Benzimidazole (generic name: omeprazole) [Reference: U.S. Patent Nos. 4,255,431, 4,337,257, 4,5
08,905, 4,758,579, UK Patent 2,134,523,
European Patent Nos. 0,005,129 and 0,268,956)
Is different from existing H ₂ -receptor antagonists in that H ⁺ , K ⁺ -A present in gastric mucosal cells as proton pump inhibitors
It shows a unique mechanism of action that suppresses the final stage of gastric acid secretion by blocking the proton pump by TPase,
It has the advantage that its duration is also longer than existing anti-ulcer drugs. Omeprazole has been demonstrated to have excellent anti-ulcer effect, far exceeding the effects of existing H ₂ -receptor antagonists such as cimetidine, pamotidine, ranitidine, nizatidine or roxatidine, and has been developed in various dosage forms Has been widely used.

[0009]

Embedded image

[0010]

DISCLOSURE OF THE INVENTION The present inventors have developed a novel anti-ulcer drug which has a benzimidazole skeleton similar to omeprazole but has a much better antiulcer effect than omeprazole. Did extensive and intensive research over a long period of time. As a result, the present inventors have synthesized a novel compound having the structure of the above general formula (I) and confirmed that this compound has an antiulcer effect exceeding that of omeprazole, thereby completing the present invention. Reached.

The present invention provides a novel compound represented by the following general formula (I):
An object is to provide a pyrrolyl-6-halogeno-2-pyridylmethylsulfinylbenzimidazole derivative, or a pharmaceutically acceptable salt thereof.

[0012]

Embedded image

Further, the present invention provides the above-mentioned 5-pyrrolyl-6-
In addition to providing a process for preparing a halogeno-2-pyridylmethylsulfinylbenzimidazole derivative and a pharmaceutically acceptable salt thereof, at least one compound of the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient is provided. It is another object of the present invention to provide a pharmaceutical composition for preventing and / or treating gastric / duodenal ulcer containing an acceptable salt.

Hereinafter, the present invention will be described in detail. That is, the present invention is a novel 5-pyrrolyl-6-halogeno-2-pyridylmethylsulfinylbenzimidazole derivative represented by the following general formula (I), or a pharmaceutically acceptable salt thereof.

[0015]

Embedded image

In the formula, X represents S, SO or SO ₂ ,
Y represents halogen; R ¹ and R ² each independently represent a hydrogen atom or an alkyl group; R ³ represents a hydrogen atom;
Alkyl group of ^{_{1 -C 8, -SR 6, -N}} (R 7) 2, 1
- piperidinyl, 4-morpholinyl group, 4-methylpiperazin-1-yl group, 1-pyrrolidinyl group, or a group of the formula -OR ⁶ or -O (CH _2), shows a group of _m -Z, wherein, R ⁶ is , alkyl group of C ₁ -C _4, C ₂ -
A C ₄ alkenyl group, an optionally substituted C ₃ -C ₁₀
Each independently by a cycloalkyl group, a C ₂ -C ₅ fluoroalkyl group, or a C ₁ -C ₄ alkyl group or an alkoxy group which may be substituted by one or more halogen atoms or halogen atoms. A substituted phenyl or benzyl group;
⁷ represents a hydrogen atom or a C ₁ -C ₅ alkyl group,
Z is a group represented by the formula —O (CH ₂ ) _p —OR ⁸ , —O (CH ₂ ) _q
-R ⁹ or _{-O (CH 2) r O (} CH 2) s -OR 10
Wherein p and q each independently represent an integer of 1 to 3, r and s
Each independently represents an integer of 1 to 5, R ⁸ represents a hydrogen atom, a lower alkyl group, an aryl group or an aralkyl group, and R ⁹ represents a hydrogen atom, an alkoxycarbonyl group, an aryl group or A heteroaryl group; R ¹⁰ represents a hydrogen atom or a lower alkyl group;
m represents an integer of any of 2 to 10, and R ⁴ and R
⁵ are each independently either a hydrogen atom or an alkyl group C ₁ -C _5, when together with the carbon atom to which R ⁴ and R ⁵ is in contact with the pyridine ring to form a ring, R ⁴ and R
³ or R ³ and R ⁵ are -CH = CH-CH = CH
_{-, - O (CH 2)} n -, - O (CH 2) n O -, - C
H ₂ (CH ₂ ) _n — or —OCH ＝ CH—;
Here, n represents an integer of 1 to 4.

In the compound of the general formula (I) of the present invention, X preferably represents S, SO or SO ₂ , Y represents a halogen atom, and R ¹ and R ² each independently represent a hydrogen atom or a methyl group, R ³ represents a hydrogen atom, C ₁ -
A C ₈ alkyl group, —SR ⁶ , —N (R ⁷ ) ₂ , 1-piperidinyl group, 4-morpholinyl group, 4-methylpiperazin-1-yl group, 1-pyrrolidinyl group, or a compound of the formula —O
And R ⁶ or —O (CH ₂ ) _m —Z, wherein R ⁶ is a C ₁ -C ₄ alkyl group, a C ₂ -C ₄ alkenyl group, or a C ₁ -C ₄ alkyl group. cycloalkyl group optionally C ₃ -C ₁₀ substituted, 3-8
C ₂ substituted by any number of fluorine atoms
R ⁷ represents a C ₅ -fluoroalkyl group or a phenyl group substituted by one or more halogen atoms or a C ₁ -C ₄ alkyl group or an alkoxy group which may be substituted by a halogen atom; represents a hydrogen atom or an alkyl group C ₁ -C _4, Z has the formula -
^{_{O (CH 2) p -OR 8}} , -O (CH 2) q -R 9 , or -O (CH ₂₎ shows a group of _{r O (CH 2) s -OR} 10, wherein, p and q, Each independently represents an integer of 1 to 3, r and s each independently represent an integer of 1 to 5, R ⁸ represents a hydrogen atom, a lower alkyl group, an aryl group or an aralkyl; R ⁹ represents a hydrogen atom, an alkoxycarbonyl group, an aryl group or a heteroaryl group;
¹⁰ represents a hydrogen atom or a lower alkyl group, m represents an integer of any of 2 to 10, and R ⁴ and R ⁵ each independently represent a hydrogen atom or a C ₁ -C ₅ alkyl group. , when together with the carbon atom to which R ⁴ and R ⁵ is in contact with the pyridine ring to form a ring, R ⁴ and R ³ or R ³ and R ⁵ are -CH = CH-CH = CH - , - O
_{(CH 2) n -, -} CH 2 (CH 2) n -, or -O
CH = CH-, wherein n is an integer from 1 to 4, wherein the oxygen atom is a compound which always exists at the R ³ position.

Preferred examples of the C ₂ -C ₄ alkenyl group for R ⁶ include a 1-propenyl group, a 3-butenyl group and isomers thereof, and a C ₃ -C ₁₀ cycloalkyl group is preferred. Examples are the cyclopropyl group, 2-
Methylcyclopropyl group, 2,2-dimethylcyclopropyl group, 2,3-diethylcyclopropyl group, 2-butylcyclopropyl group, cyclobutyl group, 2-methylcyclobutyl group, 3-propylcyclobutyl group, 2,3 , 4
-An optionally substituted cycloalkyl group such as a triethylcyclobutyl group, a 2,2-dimethylcyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group or a cyclodecyl group.

Also, one or more halogen atoms or C ₁ which may be substituted by halogen atoms
Examples of the phenyl group substituted by an alkyl group or an alkoxy group -C _4, phenyl (o-, m- or p-) tolyl, (o-, m- or p-) ethylphenyl, 2- Ethyltolyl group, 4-ethyl-o-tolyl group, 5-ethyl-m-tolyl group, (o-, m- or p-) propylphenyl group, 2-propyl (o-, m
-Or p-) tolyl group, 4-isopropyl-2,6-
A xylyl group, a 3-propyl-4-ethylphenyl group,
(2,3,4-, 2,3,6- or 2,4,5-) trimethylphenyl group, (o-, m- or p-) fluorophenyl group, (4-, 2,5-, 2 , 6-, 3,4-
Or 3,5-) difluorophenyl group, (o-, m-
Or p-) chlorophenyl group, 2-chloro-p-tolyl group, (3-, 4-, 5- or 6-) chloro-o-tolyl group, (o-, m- or p-trifluoromethyl)
Phenyl group, 4-fluoro-2,5-xylyl group, 4-
Chloro-2-propylphenyl group, 2-isopropyl-
4-chlorophenyl group, 4-chloro-3,5-xylyl group, (2,3-, 2,4-, 2,5-, 2,6- or 3,5-) dichlorophenyl group, 4-chloro-3 -Fluorophenyl group, (3- or 4-) chloro-2-fluorophenyl group, (o-, m- or p-) trifluoromethylphenyl group, (o-, m- or p-) ethoxyphenyl group, (4- or p- (4- or 5-))
There is a chloro-2-methoxy-phenyl group or a 2,4-dichloro- (5- or 6-) methylphenyl group.

Examples of C ₂ -C ₅ fluoroalkyl groups include 2,2,2-trifluoroethyl, 2,2,2
3,3,3-pentafluoropropyl group, 2,2,3
3-tetrafluoropropyl group, 1- (trifluoromethyl) -2,2,2-trifluoroethyl group, 2,2
3,3,4,4,4-heptafluorobutyl group, 2,
2,3,3,4,4,5,5-octafluoropentyl group. Y is a halogen atom, and means a fluorine atom, a chlorine atom, a bromine atom and the like.

In a particularly preferred compound of the formula (I) of the present invention, X represents S, SO or SO ₂ , Y represents a fluorine atom, and R ¹ and R ² each independently represent a hydrogen atom or methyl. R ³ represents a hydrogen atom, a methyl group, a methoxy group, an ethoxy group, an ethoxyethoxy group,
2,2,2-trifluoroethoxy group or 3,3
3,2,2- indicates pentafluoro propoxy group, R ⁴
Represents a hydrogen atom or a methyl group, and R ⁵ is a compound representing a hydrogen atom, a methyl group or an ethyl group.

The particularly preferred general formula (I) of the present invention
Wherein X represents SO, Y represents a fluorine atom,
R ¹ and R ² each independently represent a hydrogen atom or a methyl group, R ³ represents a methoxy group or an ethoxy group, R ⁴ and R ⁵ each independently represent a hydrogen atom,
It is a compound showing a methyl group or an ethyl group.

The present invention is also a process for producing the novel compound of the above general formula (I) and a pharmaceutically acceptable salt thereof. According to the method of the present invention, the compound of the general formula (I) is prepared by converting the compound of the following general formula (II) in an organic solvent in the presence of a base as shown in the following reaction formula (A). It can be obtained by reacting with a compound of the general formula (III).

[0024]

Embedded image

Wherein Y, R ¹ , R ² , R ³ , R ⁴ and R ⁵ are as defined in the above formula (I), and L is a halogen atom, an esterified hydroxyl group or an acyloxy group. Represents a group.

As a suitable reaction solvent in the reaction of the above reaction formula (A), a common organic solvent such as a lower alkanol such as methanol or ethanol, acetone, ether, tetrahydrofuran, methylene chloride, acetonitrile, dimethyl sulfoxide or dimethylformamide. Can be used, and water may be optionally added at this time. The reaction represented by the above reaction formula (A) is preferably performed at about 0 ° C. to 150 ° C., and more preferably at about 50 ° C. to 100 ° C.

As the base used in the above reaction, hydroxides, carbonates or hydrides of alkali metals or alkaline earth metals, tertiary amines and the like can be used. Examples of these compounds include sodium hydroxide,
Potassium hydroxide, potassium carbonate, calcium carbonate, sodium methoxide, sodium bicarbonate, potassium hydride, sodium hydride and pyridine, triethylamine, ethyldiisopropylamine and the like are included.

The compound of the general formula (I) of the present invention is obtained by oxidizing the compound of the general formula (Ia) using an appropriate amount of an oxidizing agent, as shown in the above reaction formula (A). You can also. In this case, the compound of the general formula (I) to be produced, the type and amount of oxidizing agent used, sulfoxide (-SO-) compound or a sulfone - becomes compound (-SO _2).

Oxidizing agents that can be used for this purpose include m-
Chloroperoxybenzoic acid, hydrogen peroxide, peroxyacetic acid, trifluoroperoxyacetic acid, 3,5-dinitroperoxybenzoic acid, peroxymaleic acid, vanadium pentoxide, nitric acid, ozone, dinitrobenzenetetraoxide, iodosobenzene, N-halo Succinimide, 1-chlorobenzotriazole, t-butyl hypochlorite, diazabicyclo [2,2,2] octane, sodium metaperiodate, cellylene oxide, manganese dioxide, chromic acid, hexanitracerium (IV) acid Examples include ammonium, bromine, chlorine or sulfuryl chloride.

This reaction is preferably carried out in an aromatic hydrocarbon such as benzene or toluene, a chlorinated hydrocarbon such as chloroform or methylene chloride, or an inert solvent such as acetone.

When the compound of the formula (Ia) is oxidized, it is generally preferred that the reaction is carried out at a temperature between -70 ° C. and the boiling point of the solvent used, and from -50 ° C. to -20 ° C.
It is more preferable to carry out at a temperature of

The compounds of the general formula (I) of the present invention also include
As shown in the following reaction formula (B), the following general formula (I
It can be obtained by reacting the compound of V) with a compound of the following general formula (V).

[0033]

[Chemical 12]

Wherein Y, R ¹ , R ² , R ³ , R ⁴ , R ⁵
Is as defined in the above general formula (I), t represents 1 or 2, and M represents an alkali metal.

The reaction of the above reaction formula (B) preferably comprises
The reaction can be performed in a usual inert solvent, and examples of such a solvent include the organic solvents described in the above reaction formula (A). The reaction represented by the above reaction formula (B) is generally performed at a temperature between 0 ° C. and 120 ° C., preferably at the boiling point of the solvent used.

The compound of the general formula (V) used as a starting material in the method of the above reaction formula (B) for producing the compound of the general formula (I) of the present invention is obtained by converting a pyridine N-oxide intermediate into phosphorus oxychloride. Alternatively, it can be produced by reacting with a chlorinating agent such as phosphorus pentachloride.

The compound of the general formula (I) of the present invention can also be obtained by reacting a compound of the following general formula (VI) with a compound of the following general formula (VII) as shown in the following reaction formula (C). Obtainable.

[0038]

Embedded image

Wherein Y, R ¹ , R ² , R ³ , R ⁴ , R ⁵
Is as defined in general formula (I) above.

The reaction of the above reaction formula (C) is carried out under the same conditions as those used in the method of the above reaction formula (A) for producing the compound of the general formula (I) of the present invention.

By oxidizing the compound of the general formula (Ia) produced by this method under the same conditions as in the above reaction formula (A), X of the general formula (I) of the present invention is A sulfonate or sulfoxide compound that is SO or SO ₂ can be produced.

The compound of the general formula (I) of the present invention can also be prepared by reacting the compound of the following general formula (VII) as shown in the following reaction formula (D).
Compound (I) can be obtained by reacting the compound of the following general formula (IX) in a polar solvent in the presence of a strong acid.

[0043]

Embedded image

Wherein Y, R ¹ , R ² , R ³ , R ⁴ , R ⁵
Is as defined in general formula (I) above.

As the polar solvent used in the reaction represented by the above reaction formula (D), water can be used in addition to a commonly used polar solvent, and a mixture of water and these polar solvents can be used. May be used. The reaction represented by the above reaction formula (D) is preferably performed at the boiling point of the solvent used in the reaction.

By oxidizing the compound of the general formula (Ia) of the present invention prepared by the method of the above reaction formula (C) or (D) in the same manner as in the method of the above reaction formula (A) The sulfonated compound or sulfoxide compound represented by the general formula (I) of the present invention can be produced.

As the starting materials used in the production method of the present invention as described above, those known per se or those produced by a known method can be used.

The compound of the general formula (I) of the present invention produced by the above-mentioned method can be separated and purified according to a general post-treatment method, or converted into a pharmaceutically acceptable salt thereof by a conventional method. Can be done. Specifically, after the formation reaction of the compound of the above general formula (I) is completed, the precipitate is separated by filtration, the solvent is distilled off from the filtrate, and crystallization is performed using the above organic solvent. Do. Alternatively, the compound (I) of the present invention can also be obtained by separation / purification by column chromatography, lyophilization, or the like. The compound (I) of the present invention thus obtained can be converted into a salt with various acids described below.

The compound of the general formula (I) of the present invention obtained as described above can be used for preventing and / or treating gastric / duodenal ulcer. The compound of the general formula (I) of the present invention has a similar structure to omeprazole which is a known anti-ulcer agent, and has a similar mechanism of action. However, from the experimental results described below, in terms of drug efficacy, not only in vitro (in vitro) experiments but also in vivo (i
(n vivo) It was also confirmed in experiments that it had a stronger effect than omeprazole. From the results of the pharmacological test and the toxicity test, it was confirmed that the compound of the formula (I) of the present invention had little acute toxicity, no toxicity on the central nervous system, and little toxicity on the cardiovascular system.

Therefore, the novel compounds of the general formula (I) of the present invention not only have an excellent effect than the already developed anti-ulcer agents, but are also excellent anti-ulcer agents having a long duration of drug effect. Was revealed.

The compound of the general formula (I) of the present invention can be administered orally or parenterally, but oral administration is more preferred.

The compounds of the general formula (I) of the present invention can be administered as such or in the form of a pharmaceutically acceptable salt thereof. Examples of suitable salts of the compounds of general formula (I) include acid addition salts or alkali metal salts. Examples of the alkali metal salt include a sodium salt, a potassium salt, a lithium salt, a magnesium salt, a calcium salt and an alkylamino salt.

Examples of the acid capable of forming an acid addition salt include sulfonic acid, phosphoric acid, nitric acid, perchloric acid, formic acid, acetic acid, propionic acid, succinic acid, gluconic acid, lactic acid, malic acid, tartaric acid and citric acid. Acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, salicylic acid, p-aminosalicylic acid, ambonic acid, methanesulfonic acid , Ethanesulfonic acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, camphorsulfonic acid, quinic acid
acid), o-methylene mandeli acid
c acid), halogen benzene sulfonic acid, methionine,
Examples include tryptophan, lysine, arginine, picric acid or do-tolyl-tartaric acid, and the compounds of the general formula (I) of the present invention include acid addition salts formed thereby.

The compound of the general formula (I) of the present invention may be a pharmaceutically acceptable additive such as a stabilizer, an excipient, a pH adjuster, various dyes, and various bases and buffers. , Can be administered in a suitable pharmaceutically acceptable dosage form using a suitable carrier such as a capsule. Such a preparation may be a solid preparation or a liquid preparation, and may be a powder, granules, various tablets, capsules, syrups, suppositories, injections, sustained release preparations, etc. The preparation may be in the form of tablets or capsules.

When the compound of the present invention is to be clinically administered to a patient for the prevention and / or treatment of gastric / duodenal ulcer, the dose to be administered depends on the condition of the ulcer, sex,
Although it depends on various factors including age, weight, environment, etc., in general, 1 kg of adult
0.05mg to 10mg, preferably 0.1m
The dose of g to 1.5 mg is administered once or in several divided doses.

The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.

[0057]

【Example】

(Example 1) 2-[[(4-methoxy-3-methyl)-
2-pyridinyl] methylthio] -5- (1H-pyrrol-
Preparation of 1-yl) -6-fluoro-1H-benzimidazole (Compound 1) 5 g (21.43 mmol) of 5- (1H-pyrrol-1-yl) -6-fluoro-2-mercaptobenzimidazole in 200 ml of methanol And 1.89 g (2 equivalents) of sodium hydroxide were sequentially added and dissolved, and 4.46 g (1 equivalent) of 4-methoxy-3-methyl-2-chloromethylpyridine hydrochloride was added to this solution, and the mixture was added at 50 to 60 ° C.
For 3 hours. After the reaction was completed, the precipitated inorganic substance formed was removed by filtration, the solvent was distilled off from the filtrate under reduced pressure, and the product was crystallized from ethyl acetate, hexane and ether to give 7.14 g of the title compound (yield Rate: 86.
8%).

Melting point: 150 ° C. ¹ H-NMR δ [DMSO-d ₆ ]: 2.2 (s, 3
H), 3.9 (s, 3H), 4.7 (s, 2H), 6.
3 (t, 2H), 7.0 (d, 1H), 7.1 (t, 2
H), 7.5 (bs, 2H), 8.3 (d, 1H)

Example 2 2-[[(4-methoxy-3)
-Methyl) -2-pyridinyl] methylsulfinyl]-
5- (1H-pyrrol-1-yl) -6-fluoro-1H
-Preparation of Benzimidazole (Compound 2) 6 g (16.29 mmol) of the compound prepared in Example 1 was dissolved in 200 ml of acetone, and then cooled to -40 ° C. Here, m-chloroperoxybenzoic acid (5
(0-60%) A solution obtained by dissolving 4.69 g in 30 ml of acetone is gradually added dropwise, and while maintaining the temperature at -40 ° C, 30
Stir for minutes. After completion of the reaction, hexane was added to the reaction mixture to crystallize the product, which was separated by filtration and washed with ether several times to obtain 5.92 g (yield: 94.6%) of the title compound.

Melting point: 170 ° C. ¹ H-NMR δ [DMSO-d ₆ ]: 2.1 (s, 3
H), 3.9 (s, 3H), 4.7-4.8 (dd, 2
H), 6.3 (t, 2H), 7.0 (d, 1H), 7.
1 (t, 2H), 7.7 (m, 2H), 8.2 (d, 1
H)

Using the same method as in Example 2, Compounds 3, 4, 5, 7, 8, and 9 were synthesized.

Example 3 2-[[(4- (2-ethoxyethoxy-3-methyl) -2-pyridinyl] methylsulfinyl] -5- (1H-pyrrol-1-yl) -6
Preparation of Fluoro-1H-benzimidazole (Compound 6) 3- (5- (1H-pyrrol-1-yl) -6-fluoro-2-mercaptobenzimidazole 3 g (12.86 mmol) and 1.13 g of sodium hydroxide in 150 ml of methanol (2 equivalents) were added in order to dissolve the mixture. To this solution was added 3.42 g (1 equivalent) of 4- (2-ethoxyethoxy-3-methyl) -2-chloromethylpyridine hydrochloride, and the mixture was added at 50 to 60 ° C. After reacting for hours, the solvent was distilled off under reduced pressure, and the product was dissolved in 150 ml of chloroform.
Cooled to -40 ° C. Here, m-chloroperoxybenzoic acid (1 equivalent) was gradually added dropwise, and the mixture was stirred for 30 minutes while maintaining the temperature at -40 ° C. Then, the solvent was distilled off from the reaction mixture under reduced pressure, and the residue was subjected to column chromatography and separated and purified from impurities using an eluent of ethyl acetate: hexane = 3: 1 to give 2.94 g of the title compound.
(Yield: 51.8%) was obtained.

Melting point: 84 ° C. ¹ H-NMR δ [DMSO-d ₆ ]: 1.1 (t, 3
H), 2.2 (s, 3H), 3.6 (q, 2H), 3.
8 (t, 2H), 4.2 (t, 2H), 4.7-4.9
(Dd, 2H), 6.3 (t, 2H), 7.0 (d, 1
H), 7.2 (t, 2H), 7.7 (m, 2H), 8.
2 (d, 1H)

Example 4 2-[[(4- (2,2,2
-Trifluoroethoxy) -3,5-dimethyl) -2-
Preparation of pyridinyl] methylsulfinyl] -5- (1H-pyrrol-1-yl) -6-fluoro-1H-benzimidazole (compound 10) 5- (1H-pyrrol-1-yl) -6-fluoro in 150 ml of methanol 3 g (12.86 mmol) of 2-mercaptobenzimidazole and 1.13 g (2 equivalents) of sodium hydroxide were sequentially added and dissolved, and 4- (2,2,2-trifluoroethoxy) -3, 5-
3.42 g of dimethyl-2-chloromethylpyridine hydrochloride
(1 equivalent), and the mixture was reacted at 50 to 60 ° C. for 3 hours.
Dissolved in 0 ml and cooled to -40 ° C.

Here, m-chloroperoxybenzoic acid (1
Equivalent) is gradually added dropwise while maintaining the temperature at −40 ° C.
Stirred for 0 minutes. The reaction mixture is then washed with sodium bicarbonate and brine, dried over sodium sulfate, then evaporated under reduced pressure and the residue is crystallized from ethyl acetate, ether and hexane to give the title 4.38 g (yield: 76.0%) of the compound was obtained.

Melting point: 190-192 ° C. ¹ H-NMR δ [DMSO-d ₆ ]: 2.2 (s, 6
H), 4.6 (q, 2H), 4.7-4.9 (dd, 2
H), 6.2 (t, 2H), 7.1 (t, 2H), 7.
6 (m, 2H), 8.2 (s, 1H)

Compounds 11 to 1 were prepared in the same manner as in Example 4.
4 was synthesized.

Example 5 2-[[(4- (methoxy-
3-methyl) -2-pyridinyl] methylsulfinyl]
-5- (1H-2,5-dimethylpyrrol-1-yl)-
6-Fluoro-1H-benzimidazole (Compound 1
Preparation of 6) 5- (1H-2,5-dimethylpyrrol-1-yl) -6-fluoro-2-mercaptobenzimidazole (4 g, 15.31 mmol) and 1.35 g of sodium hydroxide (2 equivalents) in 200 ml of methanol ) Was added in order to dissolve, and 3.18 g (1 equivalent) of 4-methoxy-3-methyl-2-chloromethylpyridine hydrochloride was added to this solution to give 5
After reacting at 0 to 60 ° C. for 3 hours, the solvent was distilled off under reduced pressure, and the product was dissolved in 200 ml of chloroform.
Cooled to 0 ° C. Here, m-chloroperoxybenzoic acid (1 equivalent) was gradually added dropwise, and the mixture was stirred for 30 minutes while maintaining the temperature at -40 ° C. The solvent was then removed from the reaction mixture for 4 hours.
The residue was subjected to column chromatography and purified with an eluent of ethyl acetate: hexane = 3: 1 to obtain 4.23 g (yield: 67.1%) of the title compound. .

Melting point: 112 ° C. ¹ H-NMR δ [DMSO-d ₆ ]: 1.9 (s, 6
H), 2.1 (s, 3H), 3.8 (s, 3H), 4.
6-4.8 (dd, 2H), 5.8 (s, 2H), 7.
0 (d, 1H), 7.6 (m, 2H), 8.1 (d, 1
H)

Compounds 15 to 23 were synthesized in the same manner as in Example 5 above.

Example 6 2-[[(4-methoxy-3)
-Methyl) -2-pyridinyl] methylsulfinyl]-
5- (1H-pyrrol-1-yl) -6-fluoro-1H
-Preparation of Benzimidazole (Compound 24) 1.3 g (3.38 mmol) of the compound prepared in Example 2 was dissolved in 20 ml of methylene chloride, and 1.35 g of sodium hydroxide dissolved in 10 ml of water was added to this solution. (1 equivalent) and stirred for 20 minutes. Next, the aqueous layer was taken out, washed several times with methylene chloride, and freeze-dried to obtain 1.12 g (yield: 81.8%) of the title compound.

Melting point: 232-234 ° C. ¹ H-NMR δ [D ₂ O]: 1.9 (s, 3H),
3.8 (s, 3H), 4.5-4.8 (dd, 2H),
6.4 (t, 2H), 6.9 (d, 1H), 7.1
(T, 2H), 7.4 (d, 1H), 7.6 (d, 1
H), 8.2 (d, 1H)

In the same manner as in Example 6, the sodium salt of another compound of the general formula (I) was produced.

Example 7 2-[[(4-methoxy-3
-Methyl) -2-pyridinyl] methylsulfinyl]-
5- (1H-pyrrol-1-yl) -6-fluoro-1H
Preparation of -benzimidazole (compound 2) 5 g (18.59 mmol) of 2- (lithium methylsulfinyl) -5- (1H-pyrrol-1-yl) -6-fluoro-benzimidazole was dissolved in 200 ml of benzene, To the solution was added 2.93 g (1 equivalent) of 2-chloro-4-methoxy-3-methyl-pyridine. The reaction mixture was refluxed for 2 hours and filtered to remove lithium chloride.
After evaporating the solvent from the reaction mixture under reduced pressure, the obtained crude product was dissolved in ethyl acetate and crystallized from ether to give 5.82 g (yield: 81.5%) of the title compound.

Melting point: 170 ° C. ¹ H-NMR δ [DMSO-d ₆ ]: 2.1 (s, 3
H), 3.9 (s, 3H), 4.7-4.8 (dd, 2
H), 6.3 (t, 2H), 7.0 (d, 1H), 7.
1 (t, 2H), 7.7 (m, 2H), 8.2 (d, 1
H)

Example 8 2-[[(4-methoxy-3
-Methyl) -2-pyridinyl] methylthio] -5- (1
Preparation of (H-pyrrol-1-yl) -6-fluoro-1H-benzimidazole (compound 1) 4-methoxy-3-methyl-2-thiomethylpyridine 6
g (35.50 mmol) in sodium hydroxide 1.5
The compound was dissolved in 250 ml of methanol containing 6 g (1.1 equivalents), and 2-chloro-5- (1H-pyrrol-1-) was added to the solution.
8.36 g of yl) -6-fluoro-benzimidazole
(1 equivalent) was added and the reaction mixture was refluxed for 2 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and the obtained product was crystallized from ether to obtain 10.85 g (yield: 83.0%) of the title compound.

Melting point: 150 ° C. ¹ H-NMR δ [DMSO-d ₆ ]: 2.2 (s, 3
H), 3.9 (s, 3H), 4.7 (s, 2H), 6.
3 (t, 2H), 7.0 (d, 1H), 7.1 (t, 2
H), 7.5 (bs, 2H), 8.3 (d, 1H)

Example 9 2-[[(4-methoxy-3)
-Methyl) -2-pyridinyl] methylthio] -5- (1
Preparation of H-pyrrol-1-yl) -6-fluoro-1H-benzimidazole (Compound 1) 5.58 g of 2-[[2- (4-methoxy-3-methyl) pyridinyl] methylthio] formic acid (26.18 Mmol) and 5 g (1 equivalent) of 5- (1H-pyrrol-1-yl) -6-fluoro-2,3-diaminobenzene.
The mixture was refluxed in 150 ml of N hydrochloric acid for 40 minutes. After the reaction mixture was cooled and neutralized with aqueous ammonia, the solution was treated with activated carbon and the reaction product was extracted with ethyl acetate. After evaporating the solvent from the extract under reduced pressure, the residue was crystallized from ether to give the title compound (2.75 g, yield: 28.6%).
I got

Melting point: 150 ° C. ¹ H-NMR δ [DMSO-d ₆ ]: 2.2 (s, 3
H), 3.9 (s, 3H), 4.7 (s, 2H), 6.
3 (t, 2H), 7.0 (d, 1H), 7.1 (t, 2
H), 7.5 (bs, 2H), 8.3 (d, 1H)

The structures and physical properties of each compound represented by the following general formula (I) produced by the same method as in Examples 1 to 9 are shown in Tables 1 and 2 below.

[0081]

Embedded image

[0082]

[0083]

[0084]

[0085]

[Table 1]

[0086]

[Table 2]

[0087] The anti-ulcer effect of the respective compound of general formula (I) of the present invention, as a pharmacological test, enzyme inhibition test, gastric secretion inhibition test, performed acidity inhibition test, also examine ED ₅₀ as an acute toxicity test confirmed. The test method and the results are shown below.

(Pharmacological activity test) (1) Enzyme inhibition test H ⁺ / K ⁺ -ATPa of the compound of the general formula (I) of the present invention
In order to investigate the inhibitory effect on
o) The test was performed. As a control compound, omeprazole [5-methoxy-2-[[(4-methoxy-3,5-
Dimethyl-2-pyridinyl) methyl] sulfinyl]-
1H-benzimidazole] was used.

As an enzyme source of H ⁺ / K ⁺ -ATPase, a microsomal fraction obtained by collecting the rabbit gastric mucosa and centrifuging at 77,000 × g by a high-speed centrifuge was used. The enzyme activity was inhibited by pre-shaking 60 μg of H ⁺ / K ⁺ -ATPase together with the sample (the compound of the present invention) at 37 ° C. for 5 minutes, and then using 4 mM of ATP as a substrate and cofactor (cofacto).
As r), 4 mM Mg ⁺⁺ and 20 mM K ⁺ were added.

The amount of inorganic phosphorus produced by the H ⁺ / K ⁺ -ATPase reaction was measured at 660 nm using a spectrophotometer. The results were obtained using the values obtained using the samples having different concentrations (n = 3 to 5).
It was determined by conversion based on the protein amount quantified by the Lowry method. The% value of each sample in which the enzyme activity was inhibited was calculated using the Litchfield-Wilcoxon method, and IC was the concentration that inhibited the enzyme activity by 50%.
₅₀ were obtained and the results are shown in Table 3 below.

[0091]

[Table 3]

(2) Gastric secretion inhibitory and acidity lowering effect test (in vivo) In the secondary test, gastric secretion inhibitory action and acidity in rats using the Shay method were used as in vivo tests. The inhibitory effect was examined. Measurements were made and compared in a normal control group, a omeprazole administration group, and a compound (test substance) administration group of the present invention. Hereinafter, a specific experiment method will be described.

That is, SD male rats (200 ± 20
g), after fasting for 24 hours by supplying only water, anesthetizing with ether, incising the abdominal cavity and ligating the pylorus, suspending the test substance in an aqueous solution of 0 to 5% CMC (carboxymethylcellulose). Alternatively, it was dissolved and administered to the duodenum.
After re-suturing the abdominal cavity and leaving it for 5 hours, it was killed with ether and the stomach was removed to collect gastric juice. This gastric juice is 10,000x
The precipitate was removed by centrifugation at 4 ° C. for 10 minutes at 4 g, and the amount and acidity of gastric juice were determined by pH 7.0 end point assay.
The total acid output was calculated by titration with 0.02N NaOH by a nt assay. The results are shown in Tables 4 and 5 below.

[0094]

[Table 4]

[0095]

[Table 5]

As is clear from the above experimental results, among the compounds represented by the general formula (I) of the present invention, compound 2,
5, 16 and 20 showed the same or stronger enzyme inhibitory action as omeprazole which is a known anti-ulcer agent, and in particular, compound 16 showed very strong gastric secretion inhibitory action and acidity lowering action in pharmacological tests. . On the other hand, compound 2 has almost the same medicinal properties as omeprazole, but has the advantage that it is easier to synthesize and has a higher yield. Table 6 below shows the ED ₅₀ values of Compounds 2, 16 and Omeprazole.

[0097]

(3) Acute toxicity test Five weeks old ICR (female, male) mice were preliminarily reared in a breeding room for one week, and then mice whose weight gain was favorable were randomly selected and divided into six groups. , Used for experiments. The administration dose was set as follows based on the maximum administration dose of 5,000 mg / kg, with the dose ratio in each group being 1.5. The test substance in powder form is suspended in 0.5% methyl cellulose,
Oral administration was performed using a 1 ml syringe. Other detailed administration conditions are shown in Table 7 below.

[0099]

1) Test Items Clinical Symptoms and Dead Animals-Clinical symptoms and dead animals due to the test substance were recorded immediately after administration and during the test period. Body Weight Changes-Body weight changes were recorded on the day of dosing, one week after dosing, and three times on the day of study termination. Necropsy findings-At the end of the study, all animals were sacrificed with diethyl ether, and changes in external organs due to the test substance were observed.

2) Test Results Clinical Symptoms and Dead Animals-During the test period, the maximum dose of 5,000 m in the group administered with Compound 2 and omeprazole
g / kg, in both female and male groups, Table 8-1
And 8-2, no specific clinical symptoms of the animal due to the test substance were observed. Weight change-The weight gain of the test animal due to the administration of the test substance was compared with that of the control group (0.5% CMC-administered group), but no significant change in body weight was observed. Table 9-
1 and Table 9-2. Gross necropsy findings-No special necropsy findings were observed in individuals who survived the duration of the study in the compound 2 and omeprazole groups.

[0102]

[Table 6]

[0103]

[Table 7]

[0104]

[Table 8]

[0105]

[Table 9]

3) Discussion In order to evaluate the safety of Compound 2, omeprazole was used as a control drug and Compound 2 was used in two mice (ICR, male and female).
Was orally administered to the mice and an acute toxicity test was carried out. As a result, the following results were obtained. As a result of the acute toxicity test of Compound 2, clinical symptoms, death cases, and autopsy findings showed that the toxicity tended to be low similarly to omeprazole. The LD ₅₀ of compound 2 and omeprazole was estimated to be 5,000 mg / kg or more, respectively. Compound 2 was considered to be a highly safe drug from the results of the acute toxicity test.

As a result of an acute toxicity test (oral administration) of Compound 2 using omeprazole as a control drug in mice (oral administration), the LD ₅₀ was as shown in Table 10 below.

[0108]

[0109]

According to the present invention, a novel 5-pyrrolyl-
A 6-halogeno-2-pyridylmethylsulfinylbenzimidazole derivative and a salt thereof can be obtained.
The imidazole derivative and the pharmaceutically acceptable salt thereof of the present invention have been confirmed to have a large effect of inhibiting enzyme, inhibiting gastric secretion and lowering acidity, and have no toxicity. Therefore, prevention of gastric / duodenal ulcer and / or Alternatively, it can be a drug useful for treatment. Furthermore, according to the method for producing the above-mentioned compound of the present invention, the above-mentioned imidazole derivative and a pharmaceutically acceptable salt thereof can be efficiently produced.

 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor, Jong Kiju, Kyung Kido, Bucheon, South Korea, Yok Gok, 3 Don Sung Weapee Tee. La-503 (72) Inventor Hongseon-gyeol Kyung-kyd Suwon-si Pal-targu Methan-don Jugong-il-tanji 6-306 (72) Inventor Bak-seon-jun South Korea Seoul Yong-dong Pog-yeon-dong 3-dong 6ga 75-2 (72) Inventor Nam San-Hun, Seoul, Seonbuk-gu, Sanwol-guk-dong 55-51 (72) Inventor Isun Mok Kyung-Kido Suwon-si Kyong-Sung Dong 1199-1 Don APT. 110-505

Claims (15)

[Claims] A compound of the following general formula (I) or a pharmaceutically acceptable salt thereof: Wherein X represents S, SO or SO ₂ , Y represents a halogen atom, R ¹ and R ² each independently represent a hydrogen atom or an alkyl group, R ³ represents a hydrogen atom, alkyl C ₁ -C _8, -S
R ⁶ , —N (R ⁷ ) ₂ , 1-piperidinyl, 4-morpholinyl, 4-methylpiperazin-1-yl, 1-
A pyrrolidinyl group , or a formula -OR ⁶ or -O (C
H ₂₎ shows a group of _m -Z, wherein, R ⁶ is, C ₁ -C ₄ alkyl group, an alkenyl group of C ₂ -C _4, substituted good C ₃ -C ₁₀ even though cycloalkyl Groups independently substituted by a C ₂ -C ₅ fluoroalkyl group, one or more halogen atoms, or a C ₁ -C ₄ alkyl group or an alkoxy group which may be substituted by a halogen atom. A phenyl group or a benzyl group; R ⁷ represents a hydrogen atom or a C ₁ -C ₅ alkyl group ; Z is a group represented by the formula —O (CH ₂ ) _p —OR ⁸ , —O (CH ₂ ) _q
—R ⁹ , or —O (CH ₂ ) _r O (CH ₂ ) _s —OR
^{10 represents} a group, wherein p and q each independently represent an integer of 1 to 3, r and s each independently represent an integer of 1 to 5, R ⁸ represents a hydrogen atom, a lower alkyl group, an aryl group or an aralkyl group; R ⁹ represents a hydrogen atom, an alkoxycarbonyl group, an aryl group, or a heteroaryl group; and R ¹⁰ represents a hydrogen atom or a lower alkyl group. And m represents an integer of any of 2 to 10, and R ⁴ and R ⁵ are each independently a hydrogen atom or C
Represents an alkyl group having ₁ -C _5, in the case of forming a ring with the carbon atom to which R ⁴ and R ⁵ is in contact with the pyridine ring,
R ⁴ and R ³ or R ³ and R ^5, -CH = CH
-CH = CH -, - O ( CH 2) n -, - O (CH 2)
_n O—, —CH ₂ (CH ₂ ) _n —, or —OCH ＝ C
H-, wherein n represents an integer of 1 to 4. ] 2. X represents S, SO or SO ₂ , Y represents a halogen atom, R ¹ and R ² each independently represent a hydrogen atom or a methyl group, and R ³ represents a hydrogen atom , alkyl group of C ₁ -C _8, -S
R ⁶ , —N (R ⁷ ) ₂ , 1-piperidinyl, 4-morpholinyl, 4-methylpiperazin-1-yl, 1-
A pyrrolidinyl group, or a formula -OR ⁶ or -O (C
H ₂₎ shows a group of _m -Z, wherein, R ⁶ represents an alkyl group of C ₁ -C _4, an alkenyl group of C ₃ -C _4, optionally substituted by C ₁ -C ₄ alkyl group cycloalkyl group optionally C ₃ -C _{10, 3} or C ₂ -C substituted by eight any number of fluorine atoms
Phenyl substituted by ₅ fluoroalkyl groups, one or more halogen atoms, or a C ₁ -C ₄ alkyl group or alkoxy group which may be substituted by one or more halogen atoms, respectively. represents a group <br/>, R ⁷ represents a hydrogen atom or an alkyl group C ₁ -C _4, Z has the formula ^{_{-O (CH 2) p -OR 8}} , -O (CH 2) q
—R ⁹ , or —O (CH ₂ ) _r O (CH ₂ ) _s —OR
^{10 represents} a group, wherein p and q each independently represent an integer of 1 to 3, r and s each independently represent an integer of 1 to 5, R ⁸ represents a hydrogen atom, a lower alkyl group, an aryl group or an aralkyl group; R ⁹ represents a hydrogen atom, an alkoxycarbonyl group, an aryl group, or a heteroaryl group; and R ¹⁰ represents a hydrogen atom or a lower alkyl group. And m represents an integer of any of 2 to 10, and R ⁴ and R ⁵ are each independently a hydrogen atom or C
Represents an alkyl group having ₁ -C _5, in the case of forming a ring with the carbon atom to which R ⁴ and R ⁵ is in contact with the pyridine ring,
R ⁴ and R ³ or R ³ and R ^5, -CH = CH
-CH = CH -, - O ( CH 2) n -, - CH 2 (CH
_{2) n} - or -OCH = CH- indicates, where n represents an integer of 1 to 4, claim 1 this time, the oxygen atoms are always characterized by the presence in R ³ position, Or a pharmaceutically acceptable salt thereof, of the above general formula (I). 3. X represents S, SO or SO ₂ , Y represents a fluorine atom, R ¹ and R ² each independently represent a hydrogen atom or a methyl group, R ³ represents a hydrogen atom, A methyl group, a methoxy group, an ethoxy group, an ethoxyethoxy group, a 2,2,2-trifluoroethoxy group, or a 3,3,3,2,2-pentafluoropropoxy group, and R ⁴ represents a hydrogen atom or methyl R ⁵ represents a group
The compound of the above general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein the compound or a salt thereof represents a hydrogen atom, a methyl group or an ethyl group. 4. X represents SO, Y represents a fluorine atom,
R ¹ and R ² each independently represent a hydrogen atom or a methyl group; R ³ represents a methoxy group, an ethoxy group or an ethoxyethoxy group; R ⁴ and R ⁵ each independently represent a hydrogen atom, a methyl The compound of the formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, which represents a group or an ethyl group. 5. The compound according to claim 1, wherein the compound of the following general formula (II) is reacted with a compound of the following general formula (III) in an organic solvent in the presence of a base. A method for producing the compound of I) or a pharmaceutically acceptable salt thereof. Embedded image [In the formula, X, Y, R ^{1 to} R ¹⁰ , m, n, and p to s are the same as those in claim 1, and L represents a halogen atom, an esterified hydroxyl group, or an acyloxy group. ] 6. The compound of the following general formula (IV) is reacted with a compound of the following general formula (V).
Or a pharmaceutically acceptable salt thereof of the general formula (I) described in the above. Embedded image [Where X, Y, Z, R ^{1 to} R ¹⁰ , m, n, p to s,
And L are the same as those in claim 5, t is 1 or 2, and M represents an alkali metal. ] 7. The method according to claim 1, wherein the compound of the following general formula (VI) is reacted with a compound of the following general formula (VII).
Or a pharmaceutically acceptable salt thereof of the general formula (I) described in the above. Embedded image [Where X, Y, Z, R ^{1 to} R ¹⁰ , m, n, and p to s are as defined in claim 5. ] 8. The compound of formula (I) according to claim 1, wherein the compound of formula (VIII) is reacted with a compound of formula (IX) in a polar solvent in the presence of a strong acid. Or a pharmaceutically acceptable salt thereof. Embedded image [Here, Y, Z, R ^{1 to} R ¹⁰ , m, n, and p to s are as defined in claim 5. ] 9. The method according to claim 5, wherein in the step of reacting the compound of the general formula (II) with the compound of the general formula (III), the reaction temperature is 0 ° C. to 150 ° C. . 10. The compound of the above formula (I) in which X represents S is oxidized, and X is SO or SO
The method of any of claims 5-9, characterized in that to obtain a compound of a ₂ Formula (I). 11. The method according to claim 10, wherein the oxidation reaction is carried out at a temperature between -70 ° C. and the boiling point of the solvent used. 12. A crystal obtained by performing an oxidation reaction in the presence of an organic solvent such as chloroform, methylene chloride or acetone, and then gradually increasing the reaction temperature to room temperature to obtain crystals. The method described in. 13. An oxidation reaction in the presence of an organic solvent that is chloroform, methylene chloride, or acetone, followed by adding at least one organic solvent selected from the group consisting of hexane, cyclohexane, ether, and petroleum ether. The method according to claim 10, wherein a crystal is obtained. 14. The method according to claim 6, wherein in the step of reacting the compound of the general formula (IV) with the compound of the general formula (V), the reaction temperature is 0 ° C. to 120 ° C. . 15. An anti-ulcer composition comprising a compound of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. [Chemical 6] Wherein X, Y, R ¹ , R ² , R ³ , R ⁴ and R ⁵ are as defined in claim 1. ]